About
Drug Delivery
Areas of Focus
Categories
Drug Delivery & FormulationBoston & New England
Team (10)
Allene M
Allene M. Diaz
Mersana Therapeutics
team_member
Andrew Hack MD
Andrew Hack MD, PhD
Mersana Therapeutics
team_member
Anna Protopapas
Anna Protopapas
Mersana Therapeutics
team_member
David Mott
David Mott
Mersana Therapeutics
team_member
Howard A
Howard A. “Skip” Burris III, MD, FASCO, FACP
Mersana Therapeutics
team_member
Kristen M
Kristen M. Hege, MD
Mersana Therapeutics
team_member
Clinical Trials (11)
View allTotal Trials
11
As Lead Sponsor
11
As Collaborator
0
Total Enrollment
1,492
By Phase
PHASE1: 9PHASE3: 1PHASE1/PHASE2: 1
By Status
COMPLETED: 5TERMINATED: 3RECRUITING: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline11 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT05514717Lead Sponsor
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
PHASE1Recruiting
162 participants
Started: Jan 24, 2023 · Completed: Apr 30, 2027
NCT05377996Lead Sponsor
A Study of XMT-1660 in Participants With Solid Tumors
PHASE1Recruiting
319 participants
Started: Aug 15, 2022 · Completed: May 31, 2027
NCT05329545Lead Sponsor
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
PHASE3Terminated
20 participants
Started: Jun 23, 2022 · Completed: Sep 29, 2023
NCT04907968Lead Sponsor
Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer
PHASE1Terminated
31 participants
Started: Jun 11, 2021 · Completed: Oct 3, 2023
NCT04396340Lead Sponsor
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
PHASE1Terminated
31 participants
Started: May 11, 2020 · Completed: Sep 30, 2022
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...